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Objectives: To determine the applicability of recombinant Klotho to 
prevent inflammation and organ injury in sepsis in man and mice.
Design: Prospective, clinical laboratory study using “warm” human 
postmortem sepsis-acute kidney injury biopsies. Laboratory study 
using a mouse model of endotoxemia.
Setting: Research laboratory at a university teaching hospital.
Subjects: Adult patients who died of sepsis in the ICU and control 
patients undergoing total nephrectomy secondary to renal can-
cer; male C57BL/6 and Klotho haploinsufficient mice.
Interventions: Lipopolysaccharide (0.05 mg/kg) injection and 
kill after 4, 8, and 24 hours. Mice received recombinant Klotho 
(0.05 mg/kg) 30 minutes prior to lipopolysaccharide (1 mg/kg) 
injection. Mice treated with saline were included as controls.
Measurements and Main Results: Quantitative reverse transcription 
polymerase chain reaction and immunohistochemical staining were 
used to quantify Klotho messenger RNA and protein expression 
in the kidney of sepsis-acute kidney injury patients and the kidney 
and brain of mice. The messenger RNA and protein expression of 
damage markers, inflammatory cytokine, chemokines, and endo-
thelial adhesion molecules were also determined in mice. Renal 
neutrophil influx was quantified. We found significantly lower renal 
Klotho messenger RNA and protein levels in sepsis-acute kidney 
injury biopsies than in control subjects. These findings were reca-
pitulated in the kidney and brain of lipopolysaccharide-challenged 
mice. Decreased Klotho expression paralleled an increase in kidney 
damage markers neutrophil gelatinase-associated lipocalin and kid-
ney injury molecule-1. Administration of recombinant Klotho prior to 
lipopolysaccharide injection attenuated organ damage, inflamma-
tion and endothelial activation in the kidney and brain of mice. Fur-
thermore, less neutrophils infiltrated into the kidneys of recombinant 
Klotho mice compared with lipopolysaccharide only treated mice.
Conclusions: Renal Klotho expression in human sepsis-acute 
kidney injury and in mouse models of sepsis was significantly 
decreased and correlated with renal damage. Recombinant Klotho 
intervention diminished organ damage, inflammation, and endothe-
lial activation in the kidney and brain of lipopolysaccharide-chal-
lenged mice. Systemic Klotho replacement may potentially be an 
organ-protective therapy for septic patients to halt acute, inflam-
matory organ injury. (Crit Care Med 2018; 46:e1196–e1203)
Key Words: acute kidney injury; delirium; endothelial activation; 
endotoxemia; Klotho; sepsis
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (1). With a mortality rate of around 25–40%, sepsis is a lead-
ing cause of mortality worldwide, especially in critically ill 
patients (2). This high mortality is both acute and long-term, 
as many patients die in subsequent months after recovery from 
sepsis (3). Furthermore, sepsis survivors often suffer from a DOI: 10.1097/CCM.0000000000003427
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range of long-term sequelae, including chronic kidney dis-
ease (CKD), cardiovascular disease, as well as cognitive and 
physical decline. A detailed understanding of sepsis-induced 
organ failure is still lacking, resulting in the lack of curative 
therapeutic options available. These options are still limited 
to antibiotic treatment and organ support and have remained 
unchanged for the last 3 decades. The development of thera-
peutic approaches for patients with sepsis is therefore sorely 
needed in order to limit and/or reverse organ injury as a result 
of sepsis.
Klotho is a single-pass transmembrane protein that is pre-
dominantly expressed in the kidney, parathyroid gland, and the 
choroid plexus in the brain (4, 5). It is proteolytically cleaved 
by the alpha-secretases ADAM10 and 17, to generate soluble 
Klotho (6–10) which is secreted into the blood, urine, or cere-
brospinal fluid (CSF) (6, 11–14). Soluble Klotho functions as a 
humoral factor with beneficial effects including suppression of 
apoptosis, cellular senescence, and fibrosis, in addition to pro-
moting autophagy and displaying antioxidative stress proper-
ties (6, 15, 16). The majority of circulating Klotho is derived 
from the kidney (6, 17).
Ischemic acute kidney injury (AKI) in mice was paralleled by 
an acute Klotho deficiency and intervention with recombinant 
Klotho (rKL) facilitated recovery of renal and extrarenal organ 
function (12, 18–20). Klotho-deficient mice display a higher 
mortality in experimental sepsis (21). Diminished Klotho lev-
els proportional to a drop in glomerular filtration rate were 
observed in mice with CKD (12). Restoration of Klotho levels 
via genetic manipulation, viral-based delivery or administra-
tion of rKL protein normalized phosphate levels, improved 
kidney function, decreased urinary protein, and ameliorated 
tubulointerstitial damage in mice (19, 22, 23). Similar to AKI, 
acute brain injury is also commonly found in sepsis patients 
and presents as delirium (24, 25). Lipopolysaccharide (LPS) 
challenge has been shown to cause CNS inflammation, microg-
lial activation and behavioral and cognitive dysfunction in 
mice (26, 27). Apart from the kidney, Klotho is also expressed 
in the choroid plexus (Supplemental Fig. 1, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E2), the part of 
the brain responsible for producing CSF and a component of 
the blood-CSF barrier (28). Systemic inflammatory conditions 
such as sepsis, have been shown to compromise the blood-CSF 
barrier function in vivo, allowing leakage from the blood into 
the CNS via the CSF (29). In mice, Klotho deletion resulted in 
cognitive impairment whereas overexpression or supplemen-
tation of Klotho improved cognitive function (30, 31).
Since Klotho has multiple organ-protective effects, its 
replacement may serve as a therapeutic strategy for septic 
patients in order to limit acute organ damage and/or prevent 
acute-to-chronic organ dysfunction. In this study, we hypoth-
esized that Klotho messenger RNA (mRNA) and protein lev-
els were reduced in postmortem kidney biopsies from septic 
patients and in the organs of LPS-treated mice. Apart from 
inflammation, disrupted microvascular integrity and result-
ing leukocyte transmigration from the blood into underly-
ing tissues are known to be drivers of organ failure in sepsis. 
We therefore additionally postulated that rKL administration 
prior to LPS challenge would have an organ-protective effect 
by attenuating inflammation and microvascular disturbances.
MATERIALS AND METHODS
Patients
Postmortem kidney biopsies were collected in patients with sep-
sis and renal failure as described elsewhere (32, 33). Patients 18 
years old and older who died of sepsis in the ICU were included 
in the study. Patients with preexisting CKD, active autoimmune 
disorders with renal involvement, and treatment with immune-
suppressive medication were excluded from this study. All 
patients were classified as having septic shock according to the 
International Sepsis Definitions (34). In addition, renal failure in 
all patients was classified according to the Risk, Injury, Failure, 
Loss of kidney function and End-stage kidney disease (RIFLE) 
criteria (35). In patients undergoing complete nephrectomy as a 
result of kidney cancer, a healthy part of tissue was isolated from 
the kidney cortex as far away as possible from the tumor. A dedi-
cated renal pathologist at our hospital assessed all biopsies and 
considered them to be healthy. Thus, we define these biopsies 
in our article as healthy. Patients with previous renal function 
loss were excluded. Written informed consent was given by the 
relatives of all septic patients. These biopsies are referred to as 
“warm” because of the short time interval between patient death 
and biopsy collection. All biopsies were taken within an average 
of 33 minutes after death or in the operating theatre immediately 
after removal of the kidney in nephrectomy patients. These mea-
sures were taken in order to avoid unwanted necropsy which may 
have tainted our pathophysiological findings. The Medical Eth-
ics Review Committee (METC) of the University Medical Center 
Groningen reviewed and waived this study (METC 2011/372).
Mice
Ten week old male C57BL/6 mice (Harlan Laboratories, Horst, 
The Netherlands) and 9 week old male Klotho haploinsuffi-
cient (Kl+/–) mice were housed in a specific pathogen-free facil-
ity, maintained on chow and water ad libitum and housed in 
temperature-controlled chambers (24°C) with a 12 hour light/
dark cycle. Generation of haploinsufficient (Klotho+/–) mice 
has been described elsewhere (36). All experiments were per-
formed in compliance with the animal ethics committee of the 
University of Groningen and Radboud University Nijmegen.
Endotoxemia Mouse Model and Klotho Intervention
C57BL/6 mice were challenged by intraperitoneal injection 
of LPS (0.05 mg/kg Escherichia coli, serotype 026:B6 (15,000 
endotoxin U/g) and killed 4, 8, and 24 hours after LPS admin-
istration. For the Klotho intervention experiments, mice were 
first intraperitoneal injected with recombinant mouse Klotho 
(rKL) (0.05 mg/kg; 1819-KL; R & D Systems, Abington, United 
Kingdom) in saline before receiving intraperitoneal LPS (1 mg/
kg) 30 minutes later. Vehicle-injected mice were administered 
the same volume of saline intraperitoneal. Mice were killed 
4 hours after the LPS or vehicle administration. Prior to kill, 
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mice were anesthetized with oxygen/isoflurane and blood was 
drawn via aortic puncture. Organs were harvested and either 
snap frozen on liquid nitrogen and stored at –80°C until fur-
ther analysis, or fixed in formalin for histological analysis.
Gene Expression Analysis by Quantitative Reverse 
Transcription Polymerase Chain Reaction
Total RNA was isolated from mouse kidney and brain cryosec-
tions using a RNAeasy Mini Plus Kit (Qiagen, Leusden, The 
Netherlands), according to the manufacturer’s instructions. 
RNA integrity was analyzed, complementary DNA synthe-
sized and quantitative reverse transcription polymerase chain 
reaction performed as described in detail (37) and briefly in 
the supplemental methods (Supplemental Digital Content 1, 
http://links.lww.com/CCM/E2).
Immunohistochemistry and Morphometric Analysis
Immunochemical staining of Klotho, VCAM-1, E-selectin, and 
Ly6G on formalin-fixed paraffin-embedded human kidney 
and mouse kidney and brain tissue is described in the supple-
mental methods (Supplemental Digital Content 1, http://links.
lww.com/CCM/E2). Stained tissue slides were scanned using 
a Hamamatsu Nanozoomer 2.0HT (Hamamatsu Photonics, 
Hamamatsu, Japan) at a magnification of 4×. Morphometric 
analysis was performed using the Aperio Imagescope positive 
pixel analysis v9.1 algorithm (Aperio Technologies, Vista, CA). 
Neutrophil infiltration was quantified by counting the number 
of neutrophils present in all glomeruli of the kidney sections.
Enzyme-Linked Immunosorbent Assay
Plasma neutrophil gelatinase-associated lipocalin (NGAL) and 
interleukin (IL)–6 and renal tissue NGAL and myeloperoxidase 
protein levels were determined by enzyme-linked immunosor-
bent assay as described in the supplemental methods (Supple-
mental Digital Content 1, http://links.lww.com/CCM/E2).
Blood Urea Nitrogen Determination
Blood urea nitrogen (BUN) quantification was performed using 
the QuantiChrom Urea Assay Kit (DIUR-100; BioAssay Systems, 
Hayward, CA) according to the manufacturer’s instructions.
Statistical Analysis
To compare two means, a two-tailed unpaired Student t test 
was used, assuming equal variances. To compare multiple 
means a one-way analysis of variance followed by Bonferroni 
post hoc analysis was used. Statistical analyses were performed 
using GraphPad Prism Software v7 (GraphPad Prism Software, 
San Diego, CA). Differences were considered significant when 
p value of less than 0.05.
RESULTS
Renal Klotho Levels Are Reduced in Critically Ill 
Patients With Sepsis-AKI
Previous studies have reported a reduction in renal Klotho 
expression in mice following ischemic-AKI (6, 15, 18, 20). 
We hypothesized that renal Klotho expression is reduced in 
human sepsis-AKI patients compared with control condi-
tions. To investigate this hypothesis we collected “warm” 
postmortem biopsies from patients who died of sepsis and 
renal failure in our ICU. Clinical and laboratory details of our 
patient biopsy cohorts can be found in Supplemental Tables 
1 and 2 (Supplemental Digital Content 1, http://links.lww.
com/CCM/E2). We found significantly lower renal Klotho 
mRNA levels in sepsis-AKI biopsies than in control subjects. 
This reduced expression paralleled increased mRNA levels of 
kidney damage markers NGAL and kidney injury molecule-1 
(Fig. 1A). Additionally, we found a clear reduction in renal 
Klotho protein levels in sepsis-AKI biopsies when compared 
with control (Supplemental Fig. 2, A and B, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E2). In our 
study, both groups of patients were of similar age, an average 
of 68 (40–83) and 65 (47–79) for sepsis and control group 
patients respectively. We found a trend (p = 0.06) suggesting a 
correlation between increasing age and reduced renal Klotho 
levels in control individuals. However, this correlation was 
completely lost in patients with sepsis (Supplemental Fig. 2C, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E2). Furthermore, the extent of Klotho mRNA and protein 
level reduction was not dependent on the degree/severity of 
renal failure as characterized in our sepsis-AKI patients using 
the RIFLE criteria (Fig. 1B; and Supplemental Fig. 2D, Sup-
plemental Digital Content 1, http://links.lww.com/CCM/E2). 
Taken together, these findings indicate that Klotho expression 
is reduced in patients with sepsis-AKI, which was accompa-
nied by an increase in kidney damage markers. Additionally, 
sepsis has a greater impact on renal Klotho levels than age.
Renal Klotho mRNA and Protein Levels Are Reduced 
in Mice Subjected to LPS Challenge
We proceeded to investigate the kinetics of renal Klotho down-
regulation using a mouse model for sepsis in which mice are 
killed at different time points after LPS challenge. The results 
reflected our observations in human sepsis-AKI, we found a sig-
nificant down-regulation in renal Klotho gene expression in LPS-
challenged mice compared with control mice (Fig. 2). Reduced 
Klotho mRNA and protein levels were already observed at 4 
hours after LPS administration (Fig. 2; and Supplemental Fig. 
3, Supplemental Digital Content 1, http://links.lww.com/CCM/
E2), and was paralleled by an up-regulation of NGAL mRNA 
(Fig. 2). Increased NGAL mRNA levels were also found in kid-
neys of Kl+/– mice compared with wild-type (WT) mice (Supple-
mental Fig. 4, Supplemental Digital Content 1, http://links.lww.
com/CCM/E2). Likewise, increased mRNA levels of E-selectin 
and intercellular adhesion molecule (ICAM)-1 as well as retinoic 
acid-inducible gene (RIG)-I, a receptor involved in the regula-
tion of LPS-mediated endothelial activation (38) were observed 
in Kl+/– mice indicating that diminished renal Klotho levels lead 
to renal damage and endothelial activation (Supplemental Fig. 4, 
Supplemental Digital Content 1, http://links.lww.com/CCM/E2). 
Interestingly, Klotho mRNA levels had not recovered by 24 hours 
after LPS challenge (Fig. 2) despite clinical recovery of the mice.
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rKL Protein Administration Protects Against LPS-
Mediated Kidney Damage and Inflammation In Vivo
In previous studies, Klotho administration was shown to 
ameliorate ischemic-AKI (6, 15). We hypothesized that 
Klotho administration prior to LPS challenge would have a 
renal protective effect. We administered rKL (0.05 mg/kg) to 
mice 30 minutes prior to LPS challenge and killed the mice 
4 hours after LPS injection. We found that rKL interven-
tion mice that received LPS had significantly lower plasma 
BUN and plasma NGAL levels compared with mice treated 
with LPS only (Supplemental Fig. 5, A and B, Supplemen-
tal Digital Content 1, http://links.lww.com/CCM/E2). Addi-
tionally, the proinflammatory cytokine IL-6 levels in plasma 
were decreased in rKL + LPS 
mice compared with LPS mice 
(Supplemental Fig. 5C, Sup-
plemental Digital Content 1, 
http://links.lww.com/CCM/
E2). Although attenuated, the 
levels of BUN, NGAL, and IL-6 
levels did not reach basal lev-
els in rKL pretreated mice. We 
found that renal NGAL mRNA 
and protein levels were also sig-
nificantly lower in rKL + LPS 
mice than in mice treated with 
LPS only (Fig. 3; and Supple-
mental Fig. 5D, Supplemental 
Digital Content 1, http://links.
lww.com/CCM/E2). Renal 
inflammation was significantly 
inhibited by rKL pretreatment, 
with lower IL-6, IL-8, and monocyte chemoattractant pro-
tein-1 mRNA expression levels in rKL + LPS mice compared 
with mice treated with LPS only (Fig. 3). We did not find any 
detrimental effects or rKL injection alone when examining 
the well-being of mice, plasma markers, and organ pathology 
(data not shown). These results collectively indicate that rKL 
administration is renoprotective in a mouse sepsis model.
rKL Protein Administration Attenuates LPS-Mediated 
Endothelial Activation and Associated Renal 
Neutrophil Infiltration
In sepsis, activated endothelial cells promote the transmigra-
tion of leukocytes from the blood into the underlying tissues 
through endothelial cell-leukocyte interactions that can be det-
rimental to organ function. We therefore proceeded to investi-
gate whether Klotho administration was also able to attenuate 
LPS-induced endothelial adhesion molecule expression in WT 
mice. Renal E-selectin and ICAM-1 mRNA expression were 
significantly reduced in rKL pretreated mice compared with 
LPS only exposure (Fig. 4). Surprisingly, vascular cell adhesion 
protein (VCAM)-1 gene expression was unaltered by Klotho 
administration prior to LPS exposure. Semiquantification of 
E-selectin and VCAM-1 protein confirmed decreased E-selec-
tin, but unaltered VCAM-1 expression in rKL pretreated mice 
compared with mice treated with LPS only (Supplemental Fig. 
6, A and B, Supplemental Digital Content 1, http://links.lww.
com/CCM/E2). Since endothelial activation plays a key role 
in immune cell infiltration into tissue, we investigated renal 
neutrophil localization. Indeed, the number of Ly6G-posi-
tive neutrophils infiltrating in the kidneys of rKL pretreated 
mice was significantly reduced compared with the number 
in LPS-only mice which was confirmed by quantification of 
the mean number of infiltrating neutrophils per glomerulus 
(Supplemental Fig. 6, C and D, Supplemental Digital Content 
1, http://links.lww.com/CCM/E2). Additionally, as a result of 
attenuated neutrophil infiltration, reduced levels of myeloper-
oxidase protein were found in rKL pretreated mice compared 
Figure 1. Renal Klotho levels are reduced in critically ill patients with sepsis-induced acute kidney injury (AKI) while 
renal damage markers are increased. A, Postmortem kidney biopsies were collected from patients with sepsis-AKI  
(n = 19). Kidney tissue was also obtained from control subjects (n = 10). Klotho, neutrophil gelatinase-associated 
lipocalin (NGAL), and kidney injury molecule (KIM)-1 messenger RNA (mRNA) expression were determined by 
quantitative reverse transcription polymerase chain reaction using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as a housekeeping gene. B, Sepsis-AKI patients (n = 19) were also categorized by the extent of renal failure, 
Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) criteria. Each dot represents an 
individual subject, and the bars represent the mean ± sd. *p < 0.05, **p < 0.005, ****p < 0.0001. ns = not significant.
Figure 2. Renal Klotho messenger RNA (mRNA) and protein levels are 
reduced in mice subjected to lipopolysaccharide (LPS) challenge. Renal 
mRNA expression of Klotho and renal damage marker neutrophil gelatinase-
associated lipocalin (NGAL) in control and LPS-challenged (0.05 mg/kg 
intraperitoneal) mice killed at the indicated time points after LPS administration. 
mRNA expression levels were determined by quantitative reverse transcription 
polymerase chain reaction using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the housekeeping gene. Each dot represents an individual 
mouse. Bars represent the mean ± sd. *p < 0.05, **p < 0.005, ***p < 0.001.
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with LPS-only treated mice (Supplemental Fig. 6E, Supple-
mental Digital Content 1, http://links.lww.com/CCM/E2). 
Taken together, our data indicate that Klotho administration 
attenuates endothelial adhesion molecule expression and neu-
trophil infiltration in the kidneys of LPS-treated mice.
Klotho Levels Are Reduced in the Brain of LPS-
Challenged Mice, and rKL Protein Administration 
Diminishes LPS-Mediated Inflammatory Activation
Our initial experiments focused on the relationship between 
Klotho and sepsis-induced AKI. However, in sepsis, multiple 
organs are affected, includ-
ing the brain. Similar to our 
findings in the kidney, we 
found a reduction in brain 
Klotho mRNA levels in 
LPS-challenged mice (Sup-
plemental Fig. 1, A and B, Sup-
plemental Digital Content 1, 
http://links.lww.com/CCM/E2). 
Based on these findings, 
we hypothesized that rKL 
intervention would attenu-
ate brain inflammation and 
microvascular disturbances 
in endotoxemic mice. We 
indeed found a reduction in 
IL-6, IL-8, IL-1β, and tumor 
necrosis factor-α mRNA 
levels in brains of rKL pre-
treated, LPS-challenged mice 
compared with LPS-only 
mice (Fig. 5). Furthermore, 
E-selectin and ICAM-1 
mRNA induction in the brain 
was also attenuated in rKL 
pretreated mice compared 
with LPS-only mice (Fig. 5). 
VCAM-1 gene expression 
levels did not differ between 
rKL + LPS and LPS-only 
mice, which is comparable 
to the results observed in the 
kidney. Our findings show 
that acute lowering of Klotho 
expression in response to LPS 
exposure is not limited to the 
kidney but also present in the 
brain. Additionally, we found 
that rKL administration pro-
tected against subsequent 
LPS-induced inflammation 
and endothelial adhesion 
molecule expression in the 
brain.
DISCUSSION
The kidney is one of the most affected organs in critical illness 
with nearly half of critically ill patients suffering from AKI. Delir-
ium is characterized by mental status impairments which, simi-
lar to AKI, can have lasting consequences in critically ill patients. 
Patients with sepsis often suffer from AKI and delirium, which 
was found to be an accelerator of existing cognitive decline (39–
41). Hence, an intervention that can reduce acute kidney “and” 
brain injury as well as limit the development of chronic kidney 
injury and cognitive decline in sepsis survivors, would provide 
an important step forward for the clinical care for sepsis patients.
Figure 3. Recombinant Klotho (rKL) protein administration protects against lipopolysaccharide (LPS)-mediated 
kidney damage and inflammation in vivo. Renal neutrophil gelatinase-associated lipocalin (NGAL), interleukin 
(IL)–6, IL-8, and monocyte chemoattractant protein (MCP)-1 messenger RNA (mRNA) expression in control, 
LPS, and rKL + LPS mice was determined by quantitative reverse transcription polymerase chain reaction 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. Each dot represents an 
individual mouse. Bars represent the mean ± sd. **p < 0.005, ***p < 0.001.
Figure 4. Recombinant Klotho (rKL) protein administration attenuates lipopolysaccharide (LPS)-mediated 
endothelial activation. Renal messenger RNA (mRNA) expression levels of E-selectin, vascular cell adhesion 
protein (VCAM)-1, and intercellular adhesion molecule (ICAM)-1 in control vehicle-treated mice (n = 8) or LPS 
(1 mg/kg) challenged mice (LPS; n = 8), or LPS (1 mg/kg) challenged mice that received recombinant Klotho 
(0.05 mg/kg) 30 min prior to LPS injection (rKL + LPS; n = 8). All mice were killed 4 hr after LPS or vehicle 
injection. Each dot represents an individual mouse. Bars represent the mean ± sd. *p < 0.05, **p < 0.005. 
GAPDH = glyceraldehyde 3-phosphate dehydrogenase, PBS = phosphate-buffered saline
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The exact pathophysiology of septic-AKI is still unknown, 
yet it is becoming increasingly clear that it is different from 
ischemic-AKI both in experimental models and in the clini-
cal situation. In contrast to findings observed in ischemic-AKI, 
we as well as others have found little evidence of severe acute 
tubular necrosis in human septic-AKI postmortem studies 
(42–44) (Aslan et al, unpublished findings, 2018). These find-
ings were recapitulated recently in an elegant experimental 
study of septic-AKI in sheep that reported that as severe sep-
tic-AKI developed, hardly any obvious renal pathologic distur-
bances were found. Renal blood flow and oxygen consumption 
were also unchanged (45). Hence, renal responses to sepsis are 
a decline in renal function almost certainly due to functional 
changes without major structural changes. Thus, the reduction 
of Klotho mRNA and protein levels which we found in septic-
AKI patients, as well as in our LPS-challenged mice is not due 
to major ischemic and apoptotic damage.
We furthermore showed that the reduction in Klotho in 
mouse endotoxemia was not limited to the kidney but also 
occurred in the brain, most probably the choroid plexus, of LPS-
treated mice. Lower expression levels of Klotho in LPS-treated 
mice remained for up to 24 hours despite clinical recovery of the 
mice. Recovery was defined by the absence of renal inflammation 
and examining the general 
well-being of the mice. It is as 
yet unclear how long it takes for 
renal Klotho levels to recover 
after LPS challenge. Using a 
low dose of LPS which we used 
in our in vivo studies, Klotho 
levels had recovered at 4 weeks 
after the initial LPS challenge 
(data not shown). The kinet-
ics of Klotho down-regulation 
and recovery in the organs of 
septic patients are unknown. 
Interestingly, renal inflamma-
tion, thought to be a driver 
of Klotho down-regulation, 
is absent at the time of biopsy 
(data not shown) and there-
fore, the low levels of Klotho 
in the human sepsis-AKI biop-
sies were not due to persistent 
inflammation but rather likely 
due to impaired recovery after 
the severe inflammatory insult 
occurring at the initial phase 
of sepsis. Removal of circulat-
ing inflammatory mediators by 
RRT after sepsis had been initi-
ated did not have any influence 
on renal Klotho levels in septic 
patients (data not shown).
The protective effect of rKL 
supports the hypothesis that 
Klotho is a mediator and not just a marker of renal damage. 
The molecular target of Klotho on cells, and a “Klotho recep-
tor” remains to be elucidated. Klotho is however known to 
interact and protect the endothelium (46–49). Since microvas-
cular integrity is disrupted, which can act as a driver of organ 
failure in sepsis, we hypothesized that rKL would attenuate 
endothelial activation in LPS-challenged mice. Diminished 
endothelial activation in both the kidney and brain of LPS-
treated mice confirmed this hypothesis, which coincided with 
less renal neutrophil influx. We recently identified RIG-I as 
an intracellular regulator of LPS-mediated endothelial activa-
tion responses (38). Klotho was shown to inhibit senescence-
associated endothelial activation and inflammation in aged 
cells and in mice via interaction with RIG-I (46). It is tempt-
ing to speculate that rKL attenuated endothelial activation and 
inflammation via RIG-I in our LPS-challenged mice.
We found peripheral injection of rKL to have protective effects 
on the brain but how this occurs is unknown. Previously, the 
uptake of labeled Klotho into different rat organs was quantified 
using autoradiographs. The kidney showed the highest uptake 
of Klotho, followed by the spleen, liver, and heart. Minimal 
uptake of Klotho was found in the brain (6), suggesting that rKL 
is unable to cross the blood brain barrier (BBB). However, the 
Figure 5. Klotho levels are reduced in the brain of endotoxemic mice and are rescued by recombinant Klotho 
administration prior to lipopolysaccharide (LPS) challenge. Brain messenger RNA (mRNA) expression levels 
of E-selectin, vascular cell adhesion protein (VCAM)-1,  intercellular adhesion molecule (ICAM)-1, neutrophil 
gelatinase-associated lipocalin (NGAL), interleukin (IL)–6, IL-8, IL-1β, and tumor necrosis factor (TNF)–α in 
control vehicle-treated mice (n = 5) or LPS (1 mg/kg) challenged mice (LPS; n = 8), or LPS (1 mg/kg) challenged 
mice that received recombinant Klotho (0.05 mg/kg) 30 min prior to LPS injection (recombinant Klotho [rKL] + 
LPS; n = 8). All mice were killed 4 hr after LPS or vehicle treatment. All mRNA expression levels were determined 
by quantitative reverse transcription polymerase chain reaction using glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the housekeeping gene. Each dot represents an individual mouse. Bars represent the mean ± sd.  
*p < 0.05, **p < 0.005, ***p < 0.001, ****p < 0.0001.
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BBB is disrupted in LPS-challenged mice (50) and therefore sys-
temic rKL may be able to cross the BBB enabling its protective 
effects. An alternative hypothesis is that the peripheral response 
of rKL mediates a protective effect on the Brain. Recently, mice 
injected with a fragment of Klotho, similar to its excreted form, 
that despite being unable to enter the brain, enhanced cognition 
and motor functions in mice (51). The ability of rKL to induce 
protective effects in multiple organs and especially the brain is of 
therapeutic value since this will bypass the need to deliver rKL 
directly into the brain. Further work is needed to elucidate exactly 
how peripheral rKL protects the brain in the setting of sepsis.
Recent studies in mice found that rKL administration in 
postischemic-AKI was found to prevent CKD progression 
(18, 20). Similarly, chronic administration of rKL was shown 
to slow down the progression of CKD and cardiac complica-
tions (20). Based on these and our own findings we speculate 
that rKL will also prevent the progression of acute-to-chronic 
organ dysfunction after sepsis recovery. However, this would 
have to be tested in additional sepsis mouse models and then 
subsequently in patients.
Sepsis survivors have a shorter life expectancy since they lose 
organ function, amongst others kidney and neurologic reserve, 
which renders them at increased risk of organ failure after recov-
ery, and the development of chronic illnesses such as CKD, car-
diovascular disease, and cognitive decline (52). These features 
resemble normal aging which suggest that critical illness can 
lead to gradual organ function decline and premature aging. 
Klotho is known to promote longevity, and conversely distur-
bances in Klotho levels or function were associated with senes-
cent phenotypes (4, 53). Hence, Klotho depletion and impaired 
recovery may drive accelerated aging in sepsis survivors.
Our study does have important limitations to consider. 
Our in vivo LPS-challenged mouse model is limited to under-
standing the initial early inflammatory responses associated 
with sepsis. The mice recover quickly which does not leave 
a large window for intervention after LPS challenge. Hence, 
the applicability of rKL to prevent organ failure, death and 
chronic disease progression in sepsis would have to be tested 
in additional septic mouse models. Recently, while this article 
was under review, such experiments were performed by Chen 
et al (54). They found that renal klotho was reduced in cecal 
ligation puncture (CLP) mice, corroborating our own find-
ings. Additionally, they found that administration of rKL 1 
hour after CLP surgery reduced renal damage as determined 
by BUN and serum creatinine levels (54). The kinetics of 
acute Klotho down-regulation in septic patient organs is also 
unknown. To do this, patients entering the ICU with suspected 
infection would have to be biopsied as early as possible before 
organ failure occurs. However, critically ill patients are rarely 
biopsied because of the inherent high risk to the patient. As a 
result, obtaining biopsies from septic patients is not desirable 
with the only remaining option being to perform the biopsy 
post mortem in nonsurvivors. All of our patients suffered 
from septic shock, but an additional nephrotoxic mechanism 
in septic patients can never be excluded. However, all known 
nephrotoxic drugs were avoided or given in such a way that 
plasma levels could be checked. Sepsis-induced AKI was deter-
mined on clinical grounds as there is currently no diagnostic 
tool to define patients. Our current study focused on investi-
gating Klotho levels septic-AKI patients. Whether this is also 
the case for nonseptic AKI critically ill patients is currently 
unknown but will be investigated in future studies. However, 
based on preclinical in vivo models, one might speculate that 
renal Klotho levels may also be reduced in other nonseptic crit-
ically ill patients. We found reduced renal Klotho levels in mice 
undergoing Haemorrhagic shock and resuscitation, a preclini-
cal model for major bleeding and trauma (data not shown), 
but the reduction was not as severe as observed in endotox-
emic or CLP mice. This suggests that the mechanism of Klotho 
depletion likely differs depending on whether infectious or 
sterile injury are the cause of AKI.
In summary, we conclude that Klotho expression in septic 
patients and in LPS-challenged mice is significantly decreased 
and negatively correlated with renal damage markers. rKL 
intervention diminished organ damage, inflammation, and 
endothelial activation in the kidney and brain of LPS-treated 
mice. Hence, Klotho replacement or treatments that prevent 
Klotho down-regulation might be a therapeutic strategy for 
septic patients to limit initial organ damage and the conse-
quent progression of chronic organ dysfunction.
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